{"id":5786,"date":"2024-09-19T08:36:34","date_gmt":"2024-09-19T13:36:34","guid":{"rendered":"https:\/\/nanostherapeutics.com\/?p=5786"},"modified":"2025-06-27T10:57:08","modified_gmt":"2025-06-27T15:57:08","slug":"nanoscope-therapeutics-to-be-featured-at-annual-euretina-congress-in-barcelona-2","status":"publish","type":"post","link":"https:\/\/nanostherapeutics.com\/es\/2024\/09\/19\/nanoscope-therapeutics-to-be-featured-at-annual-euretina-congress-in-barcelona-2\/","title":{"rendered":"Nanoscope Therapeutics se presentar\u00e1 en el Congreso Anual de EUretina en Barcelona"},"content":{"rendered":"
\n
\n
\n

<\/h1>\n<\/div>\n<\/div>\n<\/div>\n
\n
\n
\n
\n

DALLAS<\/span><\/span>,\u00a019 de septiembre de 2024<\/span><\/span>\u00a0\/PRNewswire\/ \u2014\u00a0Nanoscopio Therapeutics Inc.<\/a>, una empresa de biotecnolog\u00eda en etapa cl\u00ednica que desarrolla terapias gen\u00e9ticas para enfermedades hereditarias de la retina (ERH) y atrofia geogr\u00e1fica secundaria a la degeneraci\u00f3n macular, anunci\u00f3 hoy presentaciones en el\u00a024th<\/sup>\u00a0Congreso Euretina<\/a>\u00a0teniendo lugar en\u00a019 de septiembre<\/span>th<\/sup>-22Dakota del Norte<\/sup>\u00a0en\u00a0Barcelona, Espa\u00f1a<\/span>.<\/p>\n

Los detalles de las presentaciones son los siguientes:<\/p>\n

T\u00edtulo:<\/b>\u00a0An\u00e1lisis longitudinal del AUC de la agudeza visual corregida (MAVC) en pacientes tratados con terapia optogen\u00e9tica agn\u00f3stica de dosis baja o alta para la retinitis pigmentosa con mutaci\u00f3n MCO-010: resultados TOPLINE de 100 semanas de un estudio de fase\u00a02b<\/span>\/3 ensayo cl\u00ednico aleatorizado y controlado con placebo (RESTORE)<\/a>
Fecha de la sesi\u00f3n:\u00a0<\/b>21 de septiembre de 2024<\/span>
Tiempo de sesi\u00f3n:\u00a0<\/b>09:36 CEST<\/span>
Ubicaci\u00f3n:<\/b>115,\u00a0Centro de Convenciones Internacional de Barcelona<\/a>
Presentador:\u00a0<\/b>Jordi Mon\u00e9s, MD, PhD, Director del Institut de la M\u00e0cula y Barcelona Macula Foundation (Espa\u00f1a<\/span>)<\/p>\n

Adem\u00e1s de las medidas t\u00edpicas de eficacia en puntos temporales \u00fanicos (criterios de valoraci\u00f3n primarios y secundarios clave), el Dr. Mon\u00e9s presentar\u00e1 el an\u00e1lisis de eficacia para la mejor agudeza visual corregida (MAVC) en pacientes con retinosis pigmentaria tratados con Opsina multicaracter\u00edstica (MCO-010) utilizando el m\u00e9todo del \u00e1rea bajo la curva (AUC) que captura el beneficio del tratamiento durante todo el per\u00edodo de observaci\u00f3n de 2 a\u00f1os en RESTORE. Prof. Jordi Mon\u00e9s (Espa\u00f1a<\/span>) tambi\u00e9n presidir\u00e1 una\u00a0simposio satelital<\/a>\u00a0Se centr\u00f3 en la terapia optogen\u00e9tica para las enfermedades degenerativas del tracto respiratorio y la atrofia geogr\u00e1fica. Los detalles del simposio son los siguientes.<\/p>\n

T\u00edtulo del simposio:\u00a0<\/b>Terapias optogen\u00e9ticas para enfermedades degenerativas de la retina: avances cl\u00ednicos y actualizaciones<\/a>
Fecha:\u00a0<\/b>20 de septiembre de 2024<\/span>
Tiempo:\u00a0<\/b>9:45 am-10:45 am CEST<\/span>
09:45 CEST: Palabras de apertura, Jordi Mon\u00e9s, MD, PhD (Espa\u00f1a<\/span>)
09:48 am CEST: Enfermedades degenerativas de la retina, Arshad Khanani, MA, MD, FASRS (EE.UU<\/span>)
09:58 am CEST: Terapias optogen\u00e9ticas para IRD,\u00a0Paulo Stanga<\/span>, MD (Reino Unido)
10:08 am CEST: Terapias optogen\u00e9ticas para la degeneraci\u00f3n macular, Jordi Mon\u00e9s, MD, PhD (Espa\u00f1a<\/span>)
10:18 am CEST<\/span>:Evaluaciones de im\u00e1genes y eficacia en la evaluaci\u00f3n de pacientes con baja visi\u00f3n tratados con optogen\u00e9tica,\u00a0Usha Chakravarthy<\/span>, MD (Reino Unido)
10:28 CEST: Preguntas y respuestas, todos los ponentes, moderado por el Prof. Francesco Bandello, MD (Italia<\/span>)
Ubicaci\u00f3n:<\/b>118\/119,\u00a0Centro de Convenciones Internacional de Barcelona<\/a><\/p>\n

El equipo directivo estar\u00e1 presente en la conferencia y estar\u00e1 accesible para las reuniones.<\/p>\n

Acerca de Nanoscope Therapeutics Inc.
<\/b>Nanoscope Therapeutics est\u00e1 desarrollando terapias optogen\u00e9ticas que restauran la vista y son independientes de los genes para los millones de pacientes cegados por enfermedades degenerativas de la retina, para las cuales no existe cura. El activo principal de la compa\u00f1\u00eda, MCO-010, inform\u00f3 recientemente los resultados principales del ensayo cl\u00ednico RESTORE Fase 2b, multic\u00e9ntrico, aleatorizado, de doble enmascaramiento y controlado de forma simulada en los EE. UU. para la retinosis pigmentaria (NCT04945772<\/a>). La empresa tambi\u00e9n ha completado el ensayo de fase 2 STARLIGHT de la terapia MCO-010 en pacientes con Stargardt (NCT05417126<\/a>) y anunci\u00f3 recientemente\u00a0Planes para iniciar el ensayo de registro de fase 3<\/a>El MCO-010 ha recibido designaciones de v\u00eda r\u00e1pida de la FDA y de medicamento hu\u00e9rfano de la FDA tanto para RP como para Stargardt. Los activos precl\u00ednicos incluyen la terapia g\u00e9nica MCO-020 administrada con l\u00e1ser no viral para la atrofia geogr\u00e1fica.<\/p>\n

Contacto de inversores:<\/b>
Socios Argot
(212) 600-1902
PR@nanostherapeutics.com<\/a><\/p>\n

FUENTE Terap\u00e9utica del Nanoscopio<\/p>\n<\/div>\n<\/div>\n<\/section>\n<\/article>","protected":false},"excerpt":{"rendered":"

DALLAS,\u00a0Sept. 19, 2024\u00a0\/PRNewswire\/ \u2014\u00a0Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for inherited retinal diseases (IRDs) and geographic atrophy secondary to macular degeneration, today announced presentations at the\u00a024th\u00a0Euretina congress\u00a0taking place on\u00a0September 19th-22nd\u00a0in\u00a0Barcelona, Spain. Details for the presentations are as follows: Title:\u00a0Longitudinal AUC analysis of BCVA in patients treated with low- or high-dose MCO-010 […]<\/p>\n","protected":false},"author":6,"featured_media":5784,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_exactmetrics_skip_tracking":false,"_exactmetrics_sitenote_active":false,"_exactmetrics_sitenote_note":"","_exactmetrics_sitenote_category":0,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[13,8],"tags":[],"class_list":["post-5786","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-home-page","category-nanoscope-press-release"],"yoast_head":"\nNanoscope Therapeutics to be Featured at Annual EUretina Congress in Barcelona - Nanoscope Therapeutics<\/title>\n<meta name=\"description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanostherapeutics.com\/es\/2024\/09\/19\/nanoscope-therapeutics-to-be-featured-at-annual-euretina-congress-in-barcelona-2\/\" \/>\n<meta property=\"og:locale\" content=\"es_MX\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nanoscope Therapeutics to be Featured at Annual EUretina Congress in Barcelona - Nanoscope Therapeutics\" \/>\n<meta property=\"og:description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanostherapeutics.com\/es\/2024\/09\/19\/nanoscope-therapeutics-to-be-featured-at-annual-euretina-congress-in-barcelona-2\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanoscope Therapeutics\" \/>\n<meta property=\"article:published_time\" content=\"2024-09-19T13:36:34+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-06-27T15:57:08+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/09\/NSCOPE_SyposiumFlyer.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"800\" \/>\n\t<meta property=\"og:image:height\" content=\"1005\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Nanoscope Therapeutics\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:image\" content=\"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/09\/NSCOPE_SyposiumFlyer.jpg\" \/>\n<meta name=\"twitter:creator\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:site\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Nanoscope Therapeutics\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/09\\\/19\\\/nanoscope-therapeutics-to-be-featured-at-annual-euretina-congress-in-barcelona-2\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/09\\\/19\\\/nanoscope-therapeutics-to-be-featured-at-annual-euretina-congress-in-barcelona-2\\\/\"},\"author\":{\"name\":\"Nanoscope Therapeutics\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/5aeedc9aef0946fe8f96f98f7b1808a2\"},\"headline\":\"Nanoscope Therapeutics to be Featured at Annual EUretina Congress in Barcelona\",\"datePublished\":\"2024-09-19T13:36:34+00:00\",\"dateModified\":\"2025-06-27T15:57:08+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/09\\\/19\\\/nanoscope-therapeutics-to-be-featured-at-annual-euretina-congress-in-barcelona-2\\\/\"},\"wordCount\":441,\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/09\\\/19\\\/nanoscope-therapeutics-to-be-featured-at-annual-euretina-congress-in-barcelona-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2024\\\/09\\\/NSCOPE_SyposiumFlyer.jpg\",\"articleSection\":[\"Home Page\",\"Nanoscope Press Release\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/09\\\/19\\\/nanoscope-therapeutics-to-be-featured-at-annual-euretina-congress-in-barcelona-2\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/09\\\/19\\\/nanoscope-therapeutics-to-be-featured-at-annual-euretina-congress-in-barcelona-2\\\/\",\"name\":\"Nanoscope Therapeutics to be Featured at Annual EUretina Congress in Barcelona - Nanoscope Therapeutics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/09\\\/19\\\/nanoscope-therapeutics-to-be-featured-at-annual-euretina-congress-in-barcelona-2\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/09\\\/19\\\/nanoscope-therapeutics-to-be-featured-at-annual-euretina-congress-in-barcelona-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2024\\\/09\\\/NSCOPE_SyposiumFlyer.jpg\",\"datePublished\":\"2024-09-19T13:36:34+00:00\",\"dateModified\":\"2025-06-27T15:57:08+00:00\",\"description\":\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/09\\\/19\\\/nanoscope-therapeutics-to-be-featured-at-annual-euretina-congress-in-barcelona-2\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/09\\\/19\\\/nanoscope-therapeutics-to-be-featured-at-annual-euretina-congress-in-barcelona-2\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/09\\\/19\\\/nanoscope-therapeutics-to-be-featured-at-annual-euretina-congress-in-barcelona-2\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2024\\\/09\\\/NSCOPE_SyposiumFlyer.jpg\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2024\\\/09\\\/NSCOPE_SyposiumFlyer.jpg\",\"width\":800,\"height\":1005},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/09\\\/19\\\/nanoscope-therapeutics-to-be-featured-at-annual-euretina-congress-in-barcelona-2\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nanostherapeutics.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nanoscope Therapeutics to be Featured at Annual EUretina Congress in Barcelona\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"name\":\"Nanoscope Therapeutics\",\"description\":\"Bringing Back the Light of Hope\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"alternateName\":\"Nanoscope Therapeutics\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanostherapeutics.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\",\"name\":\"Nanoscope Therapeutics, Inc\",\"alternateName\":\"Nanoscope Therapeutics\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"width\":512,\"height\":435,\"caption\":\"Nanoscope Therapeutics, Inc\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/NSTherapeutics\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/nanoscope\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/5aeedc9aef0946fe8f96f98f7b1808a2\",\"name\":\"Nanoscope Therapeutics\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nanoscope Therapeutics estar\u00e1 presente en el Congreso Anual de EUretina en Barcelona - Nanoscope Therapeutics","description":"Nuestra plataforma de opsina multicaracter\u00edstica (MCO) es la primera en demostrar, en ensayos cl\u00ednicos, la capacidad de restaurar la visi\u00f3n en pacientes con enfermedades retinianas y p\u00e9rdida visual severa. Nanoscope ha desarrollado MCO-010, la primera y \u00fanica tecnolog\u00eda optogen\u00e9tica de amplio espectro, respuesta r\u00e1pida y ultrasensible para la restauraci\u00f3n de la visi\u00f3n, independiente del gen.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanostherapeutics.com\/es\/2024\/09\/19\/nanoscope-therapeutics-to-be-featured-at-annual-euretina-congress-in-barcelona-2\/","og_locale":"es_MX","og_type":"article","og_title":"Nanoscope Therapeutics to be Featured at Annual EUretina Congress in Barcelona - Nanoscope Therapeutics","og_description":"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.","og_url":"https:\/\/nanostherapeutics.com\/es\/2024\/09\/19\/nanoscope-therapeutics-to-be-featured-at-annual-euretina-congress-in-barcelona-2\/","og_site_name":"Nanoscope Therapeutics","article_published_time":"2024-09-19T13:36:34+00:00","article_modified_time":"2025-06-27T15:57:08+00:00","og_image":[{"width":800,"height":1005,"url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/09\/NSCOPE_SyposiumFlyer.jpg","type":"image\/jpeg"}],"author":"Nanoscope Therapeutics","twitter_card":"summary_large_image","twitter_image":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/09\/NSCOPE_SyposiumFlyer.jpg","twitter_creator":"@NSTherapeutics","twitter_site":"@NSTherapeutics","twitter_misc":{"Escrito por":"Nanoscope Therapeutics","Tiempo de lectura":"3 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nanostherapeutics.com\/2024\/09\/19\/nanoscope-therapeutics-to-be-featured-at-annual-euretina-congress-in-barcelona-2\/#article","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/2024\/09\/19\/nanoscope-therapeutics-to-be-featured-at-annual-euretina-congress-in-barcelona-2\/"},"author":{"name":"Nanoscope Therapeutics","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/5aeedc9aef0946fe8f96f98f7b1808a2"},"headline":"Nanoscope Therapeutics to be Featured at Annual EUretina Congress in Barcelona","datePublished":"2024-09-19T13:36:34+00:00","dateModified":"2025-06-27T15:57:08+00:00","mainEntityOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2024\/09\/19\/nanoscope-therapeutics-to-be-featured-at-annual-euretina-congress-in-barcelona-2\/"},"wordCount":441,"publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2024\/09\/19\/nanoscope-therapeutics-to-be-featured-at-annual-euretina-congress-in-barcelona-2\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/09\/NSCOPE_SyposiumFlyer.jpg","articleSection":["Home Page","Nanoscope Press Release"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/nanostherapeutics.com\/2024\/09\/19\/nanoscope-therapeutics-to-be-featured-at-annual-euretina-congress-in-barcelona-2\/","url":"https:\/\/nanostherapeutics.com\/2024\/09\/19\/nanoscope-therapeutics-to-be-featured-at-annual-euretina-congress-in-barcelona-2\/","name":"Nanoscope Therapeutics estar\u00e1 presente en el Congreso Anual de EUretina en Barcelona - Nanoscope Therapeutics","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2024\/09\/19\/nanoscope-therapeutics-to-be-featured-at-annual-euretina-congress-in-barcelona-2\/#primaryimage"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2024\/09\/19\/nanoscope-therapeutics-to-be-featured-at-annual-euretina-congress-in-barcelona-2\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/09\/NSCOPE_SyposiumFlyer.jpg","datePublished":"2024-09-19T13:36:34+00:00","dateModified":"2025-06-27T15:57:08+00:00","description":"Nuestra plataforma de opsina multicaracter\u00edstica (MCO) es la primera en demostrar, en ensayos cl\u00ednicos, la capacidad de restaurar la visi\u00f3n en pacientes con enfermedades retinianas y p\u00e9rdida visual severa. Nanoscope ha desarrollado MCO-010, la primera y \u00fanica tecnolog\u00eda optogen\u00e9tica de amplio espectro, respuesta r\u00e1pida y ultrasensible para la restauraci\u00f3n de la visi\u00f3n, independiente del gen.","breadcrumb":{"@id":"https:\/\/nanostherapeutics.com\/2024\/09\/19\/nanoscope-therapeutics-to-be-featured-at-annual-euretina-congress-in-barcelona-2\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanostherapeutics.com\/2024\/09\/19\/nanoscope-therapeutics-to-be-featured-at-annual-euretina-congress-in-barcelona-2\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nanostherapeutics.com\/2024\/09\/19\/nanoscope-therapeutics-to-be-featured-at-annual-euretina-congress-in-barcelona-2\/#primaryimage","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/09\/NSCOPE_SyposiumFlyer.jpg","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/09\/NSCOPE_SyposiumFlyer.jpg","width":800,"height":1005},{"@type":"BreadcrumbList","@id":"https:\/\/nanostherapeutics.com\/2024\/09\/19\/nanoscope-therapeutics-to-be-featured-at-annual-euretina-congress-in-barcelona-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nanostherapeutics.com\/"},{"@type":"ListItem","position":2,"name":"Nanoscope Therapeutics to be Featured at Annual EUretina Congress in Barcelona"}]},{"@type":"WebSite","@id":"https:\/\/nanostherapeutics.com\/#website","url":"https:\/\/nanostherapeutics.com\/","name":"Terap\u00e9utica del nanoscopio","description":"Recuperando la luz de la esperanza","publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"alternateName":"Nanoscope Therapeutics","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanostherapeutics.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/nanostherapeutics.com\/#organization","name":"Nanoscope Therapeutics, Inc","alternateName":"Nanoscope Therapeutics","url":"https:\/\/nanostherapeutics.com\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","width":512,"height":435,"caption":"Nanoscope Therapeutics, Inc"},"image":{"@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/NSTherapeutics","https:\/\/www.linkedin.com\/company\/nanoscope"]},{"@type":"Person","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/5aeedc9aef0946fe8f96f98f7b1808a2","name":"Terap\u00e9utica del nanoscopio"}]}},"_links":{"self":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/5786","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/comments?post=5786"}],"version-history":[{"count":2,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/5786\/revisions"}],"predecessor-version":[{"id":9017,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/5786\/revisions\/9017"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/media\/5784"}],"wp:attachment":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/media?parent=5786"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/categories?post=5786"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/tags?post=5786"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}